首页> 外文会议>American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics >Development of a HPLC-MS/MS assay to measure the novel angiogenesis inhibitor E-3810 in plasma. Preliminary pharmacokinetic evaluation in cancer patients
【24h】

Development of a HPLC-MS/MS assay to measure the novel angiogenesis inhibitor E-3810 in plasma. Preliminary pharmacokinetic evaluation in cancer patients

机译:培养HPLC-MS / MS测定以测量血浆中的新型血管生成抑制剂E-3810。癌症患者的初步药代动力学评估

获取原文

摘要

We have successfully developed a HPLC-MS/MS method to measure the novel anticancer agent E-3810 in plasma and to study its human pharmacokinetics during a Phase I clinical study. The dose escalation is in progress. Preliminary PK data, obtained on day 1 of treatment at the dose of 5 mg/day in 3 patients, showed a Cmax and AUCexp values (mean(+-)SD) of 94.5(+-)13.1 ng/mL and 724.7(+-)180.5 ng/mL~(*)h, respectively. The drug was eliminated from plasma with a half-life of about 24 hours.
机译:我们已成功开发了一种HPLC-MS / MS方法来测量血浆中的新型抗癌剂E-3810,并在I期临床研究期间研究其人体药代动力学。剂量升级正在进行中。在3例患者的剂量为5毫克/天的治疗时第1天获得的初步PK数据显示,CMAX和Aucexp值(平均(+ - )13.1ng / ml和724.7(+ - )分别为180.5 ng / ml〜(*)h。从血浆中除去药物,半衰期为约24小时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号